What are the effects and effects of Bosutinib?

Bosutinib is an oral targeted anti-cancer drug that belongs to the tyrosine kinase inhibitor (TKI) class of drugs. It is mainly used to treat chronic myeloid leukemia (CML), especially patients with BCR-ABL fusion gene positivity. It was developed by Pfizer of the United States with the trade name Bosulif. It has been widely used for the long-term treatment of leukemia in Europe, the United States, Japan and other countries. As one of the second and even third generation TKIs, bosutinib has unique advantages in mechanism and scope of application.

The main mechanism of action of bosutinib is to inhibit abnormally activatedBCR-ABL tyrosine kinase activity. This abnormal protein is the fundamental cause of CML and can lead to unlimited proliferation and differentiation disorders of leukemia cells. Bosutinib blocks the signaling pathway by highly selectively binding to the ABL kinase domain, thereby causing abnormal cells to stop proliferating and gradually undergo apoptosis. Compared with early drugs such as Imatinib, bosutinib also has inhibitory activity against a variety of drug-resistant mutant strains, so it is often used in clinical practice as a second- or third-line drug after failure of imatinib or dasatinib treatment.

In actual treatment, bosutinib has relatively mild pharmacological properties and is not likely to cause severe bone marrow suppression. It can maintain long-term efficacy in most patients. Studies have shown that patients using bosutinib can achieve rapid molecular responses in the early stages, with significant improvements in hematological indicators, and long-term treatment can extend progression-free survival. It also has the advantage of lower risk of pulmonary toxicity, making Bosutinib an alternative for patients who are intolerant to other TKI drugs.

In addition toCML, the research field of bosutinib is expanding. These studies are still in their early stages, but they suggest that bosutinib may become one of the future research directions for multi-targeted anti-cancer drugs.

Reference materials:https://go.drugbank.com/drugs/DB06616